Skip to main content
SpringerLink
Log in
Book cover

Circulating Tumor Cells pp 233–254Cite as

Prognostic Implications of CTC in Breast Cancer

  • Chapter
  • First Online:

  • 1584 Accesses

Part of the book series: Current Cancer Research ((CUCR))

Abstract

Circulating tumor cells (CTCs) represent an important conceptual link between a primary tumor and the development of metastatic disease, and in the setting of metastatic disease CTC have the potential to reveal important insights into the biology and behavior of the cells undergoing the metastatic process and contributing to the resistance and progression of disease over time. In breast cancer the enumeration of CTC has been demonstrated to be a strong prognostic factor for both progression and survival. The finding of elevated CTC after one cycle of cytotoxic chemotherapy are associated with a particularly poor prognosis, suggesting the need for innovative drugs and treatment strategies. Although prognosis can be important in treatment planning, enumeration of CTC has not yet led to predictive models for the selection of specific drugs or for when to stop or switch the current therapy. CTC can be effective in defining when and how often to perform radiographic extent-of-disease scans. Given the relatively modest impact the CTC enumeration has had on clinical care, the focus has been the development of new platforms to increase sensitivity to allow there detection in a larger fraction of patients and to allow biologic interrogation of these cells such that CTC might allow marker-driven treatment choices.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Morgan C (1874) Observations on cancer its pathology, and its relations to the organism and to other morbid growths. Lancet 103(2636):325–329. doi:10.1016/S0140-6736(02)48896-4

    Article  Google Scholar 

  2. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133(3421):571–573. doi:10.1016/S0140-6736(00)49915-0

    Article  Google Scholar 

  3. Ashworth TR (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aus Med J 14:146–149

    Google Scholar 

  4. Rolle A, Gunzel R, Pachmann U, Willen B, Hoffken K, Pachmann K (2005) Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse A preliminary report. World J Surg Oncol 3(1):18

    Article  PubMed Central  PubMed  Google Scholar 

  5. Choesmel V, Pierga JY, Nos C, Vincent-Salomon A, Sigal-Zafrani B, Thiery JP, Blin N (2004) Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients clinical relevance. Breast Cancer Res 6(5):R556–R570

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW (1998) Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 95(8):4589–4594

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Brugger W, Buhring HJ, Grunebach F, Vogel W, Kaul S, Muller R, Brummendorf TH, Ziegler BL, Rappold I, Brossart P, Scheding S, Kanz L (1999) Expression of MUC-1 epitopes on normal bone marrow implications for the detection of micrometastatic tumor cells. J Clin Oncol 17(5):1535–1544

    CAS  PubMed  Google Scholar 

  8. Ahr A, Scharl A, Muller M, von Minckwitz G, Gatje R, Pantel K, Kaufmann M (1999) Cross-reactive staining of normal bone-marrow cells by monoclonal antibody 2E11. Int J Cancer 84(5):502–505

    Article  CAS  PubMed  Google Scholar 

  9. Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, Bauer KD (2002) Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 8(5):1085–1091

    PubMed  Google Scholar 

  10. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897–6904

    Article  PubMed  Google Scholar 

  11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791

    Article  CAS  PubMed  Google Scholar 

  12. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF (2006) Circulating tumor cells versus imaging––predicting overall survival in metastatic breast cancer. Clin Cancer Res 12(21):6403–6409. doi:10.1158/1078-0432.CCR-05-1769, 12/21/6403 [pii]

    Article  CAS  PubMed  Google Scholar 

  13. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW (2005) Circulating tumor cells a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7):1420–1430

    Article  PubMed  Google Scholar 

  14. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V (2007) Circulating tumor cells in metastatic breast cancer biologic staging beyond tumor burden. Clin Breast Cancer 7(6):471–479

    Article  PubMed  Google Scholar 

  15. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Dieras V, Mathiot C, Mignot L, Thiery JP, Sastre-Garau X, Pierga JY (2008) Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 19(3):496–500. doi:10.1093/annonc/mdm507

    Article  PubMed  Google Scholar 

  16. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C (2009) Circulating tumor cells a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27(31):5153–5159. doi:10.1200/JCO.2008.20.6664, JCO.2008.20.6664 [pii]

    Article  PubMed  Google Scholar 

  17. Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Dieras V, Rolland E, Mignot L, Mathiot C, Bidard FC (2012) High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 23(3):618–624. doi:10.1093/annonc/mdr263

    Article  PubMed  Google Scholar 

  18. Muller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, group Ds (2012) Prognostic impact of circulating tumor cells assessed with the Cell Search System and AdnaTest Breast in metastatic breast cancer patients the DETECT study. Breast Cancer Res 14(4):R118. doi:10.1186/bcr3243

    Article  PubMed Central  PubMed  Google Scholar 

  19. Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marme F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Muller V, Janni W, Schneeweiss A, Fehm TN (2013) The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 137(2):503–510. doi:10.1007/s10549-012-2382-0

    Article  PubMed  Google Scholar 

  20. Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Caranana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer a pooled analysis of individual patient data. Lancet Oncol 15(4):406–414. doi:10.1016/S1470-2045(14)70069-5

    Article  PubMed  Google Scholar 

  21. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O’Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer SWOG S0500. J Clin Oncol 32(31):3483–3489. doi:10.1200/JCO.2014.56.2561

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W, Group SS (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106(5):dju066. doi:10.1093/jnci/dju066

    Article  PubMed Central  PubMed  Google Scholar 

  23. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26(19):3213–3221. doi:10.1200/JCO.2007.15.8923

    Article  PubMed  Google Scholar 

  24. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309. doi:10.1158/1078-0432.CCR-08-0872

    Article  PubMed  Google Scholar 

  25. Budd GT, Cristofanilli M, Terstappen LW, Ellis MJ, Stopeck A, Allard J, Matera J, Miller MC, Doyle G, Hayes DF (2004) Correlation of changes in circulating tumor cells and radiographic response to treatment in patients with metastatic breast cancer. Breast Cancer Res Treat 88:S226

    Google Scholar 

  26. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(14 Pt 1):4218–4224. doi:10.1158/1078-0432.CCR-05-2821, 12/14/4218 [pii]

    Article  CAS  PubMed  Google Scholar 

  27. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W, Messina C, Paoletti C, Muller V, Hayes DF, Piccart M, Pierga JY (2013) Clinical application of circulating tumor cells in breast cancer overview of the current interventional trials. Cancer Metastasis Rev 32(1-2):179–188. doi:10.1007/s10555-012-9398-0

    Article  PubMed Central  PubMed  Google Scholar 

  28. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M (2005) Detection of circulating epithelial cells in the blood of patients with breast cancer comparison of three techniques. Br J Cancer 92(5):906–912

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24(23):3756–3762. doi:10.1200/JCO.2005.04.5948

    Article  CAS  PubMed  Google Scholar 

  30. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S (2012) Circulating tumour cells in non-metastatic breast cancer a prospective study. Lancet Oncol 13(7):688–695. doi:10.1016/S1470-2045(12)70209-7

    Article  PubMed  Google Scholar 

  31. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27(13):2177–2184. doi:10.1200/JCO.2008.18.0497

    Article  CAS  PubMed  Google Scholar 

  32. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24):8152–8162

    Article  PubMed  Google Scholar 

  33. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738–2746

    CAS  PubMed  Google Scholar 

  34. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353–360. doi:10.1038/nature11143

    PubMed Central  CAS  PubMed  Google Scholar 

  35. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399. doi:10.1038/nature10933

    CAS  PubMed  Google Scholar 

  36. Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D’Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnbaum D, Wong ST, Zhan M, Chang JC, Wicha MS (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2(1):78–91. doi:10.1016/j.stemcr.2013.11.009

    Article  CAS  Google Scholar 

  37. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM (2012) Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 11(11):2526–2534. doi:10.1158/1535-7163.MCT-12-0460

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Aceto N, Bardia A, Miyamoto David T, Donaldson Maria C, Wittner Ben S, Spencer Joel A, Yu M, Pely A, Engstrom A, Zhu H, Brannigan Brian W, Kapur R, Stott Shannon L, Shioda T, Ramaswamy S, Ting David T, Lin Charles P, Toner M, Haber Daniel A, Maheswaran S (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158(5):1110–1122. doi:10.1016/j.cell.2014.07.013

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239. doi:10.1038/nature06385

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C, Lin J, Ramnath N, Wicha MS, Hayes DF, Simeone DM, Nagrath S (2013) Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol 8(10):735–741. doi:10.1038/nnano.2013.194

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107(43):18392–18397. doi:10.1073/pnas.1012539107

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Gupta V, Jafferji I, Garza M, Melnikova VO, Hasegawa DK, Pethig R, Davis DW (2012) ApoStream(), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics 6(2):24133. doi:10.1063/1.4731647

    Article  PubMed  Google Scholar 

  43. Yoon HJ, Kozminsky M, Nagrath S (2014) Emerging role of nanomaterials in circulating tumor cell isolation and analysis. ACS Nano 8(3):1995–2017. doi:10.1021/nn5004277

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, Martel JM, Kojic N, Smith K, Chen PI, Yang J, Hwang H, Morgan B, Trautwein J, Barber TA, Stott SL, Maheswaran S, Kapur R, Haber DA, Toner M (2014) Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 9(3):694–710. doi:10.1038/nprot.2014.044

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Wyatt Shields Iv C, Reyes CD, Lopez GP (2015) Microfluidic cell sorting a review of the advances in the separation of cells from debulking to rare cell isolation. Lab Chip 15(5):1230–1249. doi:10.1039/c4lc01246a

    Article  Google Scholar 

  46. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ (2010) Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 16(20):5011–5018. doi:10.1158/1078-0432.CCR-10-1105

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Zhou MD, Hao S, Williams AJ, Harouaka RA, Schrand B, Rawal S, Ao Z, Brenneman R, Gilboa E, Lu B, Wang S, Zhu J, Datar R, Cote R, Tai YC, Zheng SY (2014) Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells. Sci Rep 4:7392. doi:10.1038/srep07392

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11(4):R59. doi:10.1186/bcr2349

    Article  PubMed Central  PubMed  Google Scholar 

  49. Paoletti C, Muniz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown M, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF (2015) Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor positive breast cancer. Clin Cancer Res 21:2487. doi:10.1158/1078-0432.ccr-14-1913

    Article  CAS  PubMed  Google Scholar 

  50. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K (2010) Detection and HER2 expression of circulating tumor cells prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16(9):2634–2645. doi:10.1158/1078-0432.CCR-09-2042

    Article  CAS  PubMed  Google Scholar 

  51. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D (2007) Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25(33):5194–5202. doi:10.1200/JCO.2007.11.7762

    Article  PubMed  Google Scholar 

  52. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV, Terstappen LW (2002) Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 21(5):1111–1117

    CAS  PubMed  Google Scholar 

  53. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Janne PA, Krop IE (2010) Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 102(10):1495–1502. doi:10.1038/sj.bjc.6605676

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Payne RE, Yague E, Slade MJ, Apostolopoulos C, Jiao LR, Ward B, Coombes RC, Stebbing J (2009) Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10(1):51–57. doi:10.2217/14622416.10.1.51

    Article  CAS  PubMed  Google Scholar 

  55. Kallergi G, Mavroudis D, Georgoulias V, Stournaras C (2007) Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13(1-2):79–88. doi:10.2119/2006-00083.Kallergi

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Danila DC, Fleisher M, Scher HI (2011) Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17(12):3903–3912. doi:10.1158/1078-0432.CCR-10-2650

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13(12):3611–3616. doi:10.1158/1078-0432.CCR-07-0268

    Article  PubMed  Google Scholar 

  58. Smerage JB, Budd GT, Doyle GV, Brown M, Paoletti C, Muniz M, Miller MC, Repollet MI, Chianese DA, Connelly MC, Terstappen LW, Hayes DF (2013) Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol 7(3):680–692. doi:10.1016/j.molonc.2013.02.013

    Article  CAS  PubMed  Google Scholar 

  59. Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, Bonciarelli G, Tumolo S, Ghiotto C, Magro C, Jirillo A, Indraccolo S, Amadori A, Zamarchi R (2010) M30 neoepitope expression in epithelial cancer quantification of apoptosis in circulating tumor cells by Cell Search analysis. Clin Cancer Res 16(21):5233–5243. doi:10.1158/1078-0432.CCR-10-1449

    Article  CAS  PubMed  Google Scholar 

  60. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101(25):9393–9398. doi:10.1073/pnas.0402993101

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC (2014) Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 32(5):479–484. doi:10.1038/nbt.2892

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C (2014) Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 11(3):129–144. doi:10.1038/nrclinonc.2013.253

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Breast Oncology Program of the Comprehensive Cancer Center, University of Michigan Health and Hospital System, 1500 E. Medical Center Drive SPC 5843, Ann Arbor, MI, 48109-5843, USA

    Jeffrey B. Smerage M.D., Ph.D.

Authors
  1. Jeffrey B. Smerage M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey B. Smerage M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Jackson Memorial Hospital, University of Miami, Miami, Florida, USA

    Richard J. Cote

  2. University of Miami, Miami, Florida, USA

    Ram H. Datar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Smerage, J.B. (2016). Prognostic Implications of CTC in Breast Cancer. In: Cote, R., Datar, R. (eds) Circulating Tumor Cells. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3363-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3363-1_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-3361-7

  • Online ISBN: 978-1-4939-3363-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation